Biodesix’s (BDSX) Outperform Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Biodesix (NASDAQ:BDSX) in a report released on Tuesday,RTT News reports. William Blair also issued estimates for Biodesix’s Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Trading Down 2.3 %

NASDAQ:BDSX opened at $0.85 on Tuesday. Biodesix has a 52 week low of $0.64 and a 52 week high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a market cap of $123.65 million, a PE ratio of -2.18 and a beta of 1.10. The business’s 50 day moving average is $1.08 and its two-hundred day moving average is $1.40.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The firm had revenue of $20.43 million for the quarter, compared to analysts’ expectations of $19.92 million. On average, analysts predict that Biodesix will post -0.35 EPS for the current year.

Insider Activity at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now directly owns 701,947 shares in the company, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 128,702 shares of company stock valued at $118,406 in the last quarter. Insiders own 69.20% of the company’s stock.

Institutional Trading of Biodesix

Several hedge funds have recently made changes to their positions in the stock. Balyasny Asset Management L.P. acquired a new stake in Biodesix in the fourth quarter worth $29,000. Barclays PLC boosted its holdings in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after acquiring an additional 21,179 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Biodesix during the fourth quarter worth about $52,000. MYDA Advisors LLC acquired a new stake in shares of Biodesix in the 4th quarter worth about $76,000. Finally, Cubist Systematic Strategies LLC lifted its position in Biodesix by 385.9% in the 4th quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company’s stock valued at $78,000 after purchasing an additional 40,524 shares during the last quarter. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.